Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care® (AJMC®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More